Orticumab

Last updated September 07, 2025

This article relies largely or entirely on a single source . Relevant discussion may be found on the talk page. Please help improve this article by introducing citations to additional sources.
Find sources: "Orticumab" – news · newspapers · books · scholar · JSTOR (September 2025)

Orticumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	oxLDL
Clinical data
ATC code	none
Identifiers
CAS Number	1314241-10-5
ChemSpider	none
UNII	2O892R8U24

Orticumab (INN) is a human monoclonal antibody that is used as an anti-inflammatory agent and binds to oxLDL. It acts as an immunomodulator.^[1]

References

↑ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).

Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems

Bone

Human	Burosumab Denosumab
Humanized	Blosozumab ^† Romosozumab

Musculoskeletal

Human	Stamulumab ^†

Circulatory

Human	Abelacimab Alirocumab Ascrinvacumab ^§ Bentracimab ^† Enoticumab Evinacumab Evolocumab Icrucumab Inclacumab Marstacimab Nesvacumab Orticumab Ramucirumab Rinucumab
Mouse	Biciromab ^‡ Imciromab ^‡
Chimeric	Abciximab Volociximab
Humanized	Alacizumab pegol Bevacizumab/Ranibizumab Bococizumab Brolucizumab Caplacizumab Concizumab Demcizumab Emicizumab Etaracizumab Faricimab Idarucizumab Ralpancizumab Tadocizumab Vanucizumab

Neurologic

Human	Anti-amyloid drugs Aducanumab ^‡ Donanemab Gantenerumab ^† Lecanemab Erenumab Fasinumab ^† Fulranumab Opicinumab
Humanized	Bapineuzumab ^† Crenezumab ^† Eptinezumab Fremanezumab Galcanezumab Ozanezumab Ponezumab Refanezumab Semorinemab Solanezumab Tanezumab ^†

Angiogenesis inhibitor

Humanized	Ranibizumab

Growth factor

Human	Bimagrumab Trevogrumab
Humanized	Domagrozumab Landogrozumab

^# WHO-EM
^‡ Withdrawn from market
Clinical trials:
- ^† Phase III
- ^§Never to phase III

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.